100 related articles for article (PubMed ID: 9549355)
1. [Design and development of controlled release of drugs from injectable microcapsules].
Takada S; Ogawa Y
Nihon Rinsho; 1998 Mar; 56(3):675-9. PubMed ID: 9549355
[TBL] [Abstract][Full Text] [Related]
2. [Once-a-month injectable microcapsules of leuprorelin acetate].
Toguchi H; Ogawa Y; Okada H; Yamamoto M
Yakugaku Zasshi; 1991 Aug; 111(8):397-409. PubMed ID: 1795229
[TBL] [Abstract][Full Text] [Related]
3. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
Okada H; Heya T; Ogawa Y; Shimamoto T
J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
[TBL] [Abstract][Full Text] [Related]
4. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.
Okada H; Doken Y; Ogawa Y; Toguchi H
Pharm Res; 1994 Aug; 11(8):1143-7. PubMed ID: 7971715
[TBL] [Abstract][Full Text] [Related]
5. Controlled release of thyrotropin releasing hormone from microspheres: evaluation of release profiles and pharmacokinetics after subcutaneous administration.
Heya T; Mikura Y; Nagai A; Miura Y; Futo T; Tomida Y; Shimizu H; Toguchi H
J Pharm Sci; 1994 Jun; 83(6):798-801. PubMed ID: 9120809
[TBL] [Abstract][Full Text] [Related]
6. Application of a spray drying technique in the production of TRH-containing injectable sustained-release microparticles of biodegradable polymers.
Takada S; Uda Y; Toguchi H; Ogawa Y
PDA J Pharm Sci Technol; 1995; 49(4):180-4. PubMed ID: 7552237
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of thyrotrophin releasing hormone release from copoly(dl-lactic/glycolic acid) microspheres.
Heya T; Okada H; Ogawa Y; Toguchi H
J Pharm Sci; 1994 May; 83(5):636-40. PubMed ID: 8071811
[TBL] [Abstract][Full Text] [Related]
8. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
Luan X; Bodmeier R
J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
[TBL] [Abstract][Full Text] [Related]
9. Utilization of an amorphous form of a water-soluble GPIIb/IIIa antagonist for controlled release from biodegradable microspheres.
Takada S; Kurokawa T; Miyazaki K; Iwasa S; Ogawa Y
Pharm Res; 1997 Sep; 14(9):1146-50. PubMed ID: 9327440
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of depot leuprorelin.
Periti P; Mazzei T; Mini E
Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance.
Toguchi H
J Int Med Res; 1990; 18 Suppl 1():35-41. PubMed ID: 2138986
[TBL] [Abstract][Full Text] [Related]
12. Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer.
Ogawa Y; Yamamoto M; Takada S; Okada H; Shimamoto T
Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1502-7. PubMed ID: 3138032
[No Abstract] [Full Text] [Related]
13. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits.
Singh S; Singh J
Int J Pharm; 2007 Jan; 328(1):42-8. PubMed ID: 16959451
[TBL] [Abstract][Full Text] [Related]
14. A new animal model for evaluation of long-term growth rate over one month by rhGH/PLGA microcapsule formulations.
Takada S; Kurokawa T; Misaki M; Taira K; Yamagata Y
J Pharm Pharmacol; 2003 Jul; 55(7):951-61. PubMed ID: 12906752
[TBL] [Abstract][Full Text] [Related]
15. Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate.
Okada H; Doken Y; Ogawa Y
J Pharm Sci; 1996 Oct; 85(10):1044-8. PubMed ID: 8897268
[TBL] [Abstract][Full Text] [Related]
16. A new injectable liquid crystal system for one month delivery of leuprolide.
Ki MH; Lim JL; Ko JY; Park SH; Kim JE; Cho HJ; Park ES; Kim DD
J Control Release; 2014 Jul; 185():62-70. PubMed ID: 24794897
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable microspheres in drug delivery.
Okada H; Toguchi H
Crit Rev Ther Drug Carrier Syst; 1995; 12(1):1-99. PubMed ID: 8521523
[TBL] [Abstract][Full Text] [Related]
18. Injectable PLGA/Hydroxyapatite/Chitosan Microcapsules Produced by Supercritical Emulsion Extraction Technology: An In Vitro Study on Teriparatide/Gentamicin Controlled Release.
Della Porta G; Campardelli R; Cricchio V; Oliva F; Maffulli N; Reverchon E
J Pharm Sci; 2016 Jul; 105(7):2164-72. PubMed ID: 27290629
[TBL] [Abstract][Full Text] [Related]
19. Formulation study of leuprorelin acetate to improve clinical performance.
Toguchi H
Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
[TBL] [Abstract][Full Text] [Related]
20. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
